Amphista Therapeutics appoints new chairman, Joshua T. Brumm
– Utrecht, The Netherlands & Glasgow, Scotland - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista’s CEO Dr Nicola…
Nyxoah announces U.S. FDA breakthrough device designation granted for the Genio® system for obstructive sleep apnea and complete concentric collapse
– Utrecht (the Netherlands) & Cambridge (Massachusetts - US) - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced…
AM-Pharma signs exclusive license agreement with Kyowa Kirin for commercialization of ilofotase alfa in Japan
– Utrecht, The Netherlands & Tokyo, Japan - AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new value through the…
Noema Pharma initiates Phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome
– First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel – Noema Pharma, a Swiss-based clinical stage company targeting orphan…
Spire Health closes $38 million financing round led by Gilde Healthcare to advance respiratory remote patient monitoring
– San Francisco (California, US) & Cambridge (Massachusetts, US) – Spire Health, the leading provider of respiratory remote patient monitoring (RPM), today announced the closing of a $38 million equity financing, led by Gilde Healthcare Partners along with a leading global medtech strategic…
LAVA Therapeutics announces treatment of first patient in Phase 1/2a clinical trial
– LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia Utrecht (the Netherlands) & Philadelphia (US) – Gilde Healthcare portfolio company LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology…
Adcendo appoints Michael Pehl as Chief Executive Officer
– Utrecht (the Netherlands) & Copenhagen (Denmark) – Gilde Healthcare portfolio company Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer…
Gilde Healthcare portfolio company Nyxoah realizes successful IPO at NASDAQ
– Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium) – Gilde Healthcare portfolio company Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today started trading on NASDAQ. Gross…
Gilde Healthcare portfolio company CVRx realizes successful IPO at Nasdaq
– Utrecht (the Netherlands) & Minneapolis (USA) – Gilde Healthcare portfolio company CVRx Inc., a commercial-stage medical device company focused on innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced on Tuesday, June 29,…
Nyxoah BETTER SLEEP trial reaches its primary endpoints
– Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium) – Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the BETTER SLEEP trial reached its primary safety and…
Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital
– Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development…
Gilde Healthcare acquires majority stake in Danish drug development consultancy KLIFO to support international growth ambitions
– Northern European integrated drug development consultancy aims to further expand service offering and geographical footprint Utrecht (the Netherlands) and Copenhagen (Denmark) – Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug…
Gilde Healthcare participates in €51M series A financing of Danish biopharmaceutical start-up ADCendo
– Utrecht (the Netherlands) and Copenhagen (Denmark) – ADCendo ApS (“Adcendo”), a Danish biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a €51 million ($62 million) Series A financing. The global…
The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med
– Investment to support the global expansion of leading manufacturer of precision medical components and devices Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international…
Gilde Healthcare supports national roll out of dental chain Tandarts Today
– Utrecht and Eindhoven (the Netherlands) – Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, announces its investment in dental chain Tandarts Today. With this acquisition, Gilde Healthcare enters the Dutch Dental Care Market with its attractive…
RAD-x adds Medizin Center Bonn to its fast growing diagnostic imaging platform
– Utrecht (the Netherlands) and Mannheim (Germany) – RAD-x, the leading European diagnostic imaging practice operator and portfolio company of Gilde Healthcare Private Equity, is adding Medizin Center Bonn (MCB) to its group. MCB provides cutting-edge premier nuclear medicine- and radiology…
LUMICKS raises $93 million in Series D financing
– Amsterdam, the Netherlands – LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing. The funding…
Gilde Healthcare announces successful pricing of Nasdaq IPO of portfolio company, Lava Therapeutics
– Utrecht, the Netherlands – Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, today announced that its portfolio company, LAVA Therapeutics (Nasdaq: LVTX), has successfully achieved pricing of its Nasdaq initial public offering (IPO), expected…
Amphista Therapeutics raises $53M in Series B round co-led by Gilde Healthcare to advance next generation targeted protein degradation assets
– Amphista Therapeutics today announced the closing of a $53 million (£38 million) Series B financing round from an investor syndicate co-led by Gilde Healthcare. The proceeds will be used to accelerate the company’s growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.
Axonics® expands into stress urinary incontinence with the acquisition of Bulkamid®
– IRVINE, California US – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, last week announced that…
Ace Pharmaceuticals strengthens shareholders base
– Zeewolde, the Netherlands – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholders base with the addition of Gilde Buy Out Partners and Gilde Healthcare. Founded in 1990 and based in Zeewolde, Ace focuses on the development,…
LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic
– Utrecht, The Netherlands and Philadelphia, USA – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Dr. Kapil Dhingra as chairman…
Acacia Pharma (EURONEXT: ACPH) raises EUR 27 million for US launch
– Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or…